

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

- 1. (withdrawn):** A method for treatment of neuropsychiatric disorders which comprises administration of a D-serine transport inhibitor at a dose sufficient to enhance NMDA receptor-mediated neurotransmission in vivo.
- 2. (withdrawn):** The method of claim 1 wherein the disorder is associated with decreased *N*-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission.
- 3. (withdrawn):** The method of claim 1 wherein the disorder is a psychotic disorder.
- 4. (withdrawn):** The method of claim 3 wherein the psychotic disorder is schizophrenia.
- 5. (withdrawn):** The method of claim 1 wherein the disorder is Alzheimer's disease, bipolar illness, depression and anxiety disorders, stroke or epilepsy.

6. **(withdrawn):** The method of claim 1 wherein the disorder is age associated memory impairment, closed head injury or attention deficit disorder.
7. **(withdrawn):** The method of claim 1 wherein such agent is administered orally.
8. **(withdrawn):** The method of claim 1 wherein a D-serine transport inhibitor is administered parenterally.
9. **(withdrawn):** A method for augmentation of *N-methyl-D*-aspartate receptor-mediated neurotransmission in vivo which comprises administration of a D-serine transport antagonist.
10. **(withdrawn):** The method of claim 1 or 9 wherein the antagonist is an inhibitor of D-serine transport mediated through system ASC.
11. **(withdrawn):** The method of claim 1 or 9 wherein the antagonist is an inhibitor of systems L, N, A or Gly.
12. **(withdrawn):** The method of claim 1 or 9 wherein the antagonist is an inhibitor of alanine-sensitive D-serine transport.

**13. (withdrawn):** The method of claim 1 or 9 where the antagonist is an inhibitor of alanine-insensitive D-serine transport.

**14. (withdrawn):** The method of claim 1 or 9 wherein the agent is glycyldodecylamide, D-serine dodecylamide (d-ser-da) or D-alanine dodecylamide.

**15. (withdrawn):** The method of claim 1 or 9 wherein the agent is used in combination with typical or atypical antipsychotics administered orally, parenterally or by depot formulation.

**16. (withdrawn):** The method of claim 1 or 9 wherein the agent is used in combination with other treatments commonly used in schizophrenia, including but not limited to antidepressants, mood stabilizers, or antianxiety agents.

**17. (withdrawn):** The method of claim 1 or 9 wherein the agent is used in combination with a glycine transport inhibitor.

**18. (currently amended):** A composition for treating schizophrenia comprising an effective amount of a selective D-serine transport inhibitor comprising a serine or alanine compound having a hydrophobic group selected from the group consisting of a C1-C13 alkyl

group, a phenyl group, a C1-C13 phenylalkyl group, a cyano group, a halogen group and a C1-C13 haloalkyl group, which is linked to at least one of the C- and N-terminus of the serine or alanine compound as the active ingredient and a pharmaceutically acceptable carrier.

**19. (currently amended):** The composition of claim 18, wherein the D-serine transport inhibitor is D-alanine dodecylamide.

**20. (canceled).**

**21. (previously presented):** The composition of claim 18, wherein the D-serine transport inhibitor is present in an amount sufficient to augment NMDA-mediated neurotransmission and is combined with a typical or atypical antipsychotic agent administerable orally or parenterally.

**22. (canceled).**

**23. (canceled).**

**24. (canceled).**

**25. (withdrawn):** A method of claim 1 wherein a composition of claim 20 is used.

**26. (withdrawn):** A method of claim 9 wherein a composition of claim 20 is used.

**27-44 (canceled).**

**45. (new):** The composition of claim 18, wherein the D-serine transport inhibitor has at least 5-fold selectivity.